A three-amino-acid peptide targeting liver health and the GI tract—with a single rat hepatoprotection study and no controlled human evidence.

Ovagen is a synthetic tripeptide consisting of L-glutamic acid, L-aspartic acid, and L-leucine, joined in a peptide chain. Its molecular weight is approximately 361 daltons, making it heavier than the dipeptides (Vilon, Thymogen, Vesilute) but lighter than the larger tetrapeptides (Pancragen, Prostamax, Testagen). It was developed as part of Vladimir Khavinson's bioregulator program—the same research initiative that produced Vilon, Thymogen, and nine other organ-targeted peptides at the St. Petersburg Institute of Bioregulation and Gerontology.

Ovagen's designated target is the liver, with secondary interest in gastrointestinal tract function. The compound exists in a crowded subspace: Cluster S includes at least three liver-targeted peptides (Ovagen, Livagen, and Hepatigen), creating an immediate editorial question about specificity and overlap. Livagen has the strongest mechanistic evidence—ex vivo human chromatin data. Ovagen occupies the weakest position: a single animal study from 2012, no PubMed-indexed English-language abstracts, and no published human data accessible in English.

This is the most vulnerable compound in the Khavinson bioregulator family. It is not a failed clinical trial (Thymogen). It is not a coherent preclinical story (Vilon, Pancragen, Livagen). It is a hypothesis—a single animal observation published by the paradigm's creators, followed by silence.

For readers evaluating Ovagen, the central question is not "is this compound approved?" or "how strong is the evidence?" The question is "why should a reader in 2026 give this any weight compared to liver-support peptides with either more evidence (Livagen) or actual human data (established drugs like GLP-1 RAs or SGLT-2 inhibitors)?"

Quick Facts: Ovagen at a Glance

What Is Ovagen?

Pronunciation: OH-vah-jen

Ovagen is a synthetic tripeptide—a molecule made of exactly three amino acids: L-glutamic acid, L-aspartic acid, and L-leucine, joined by two peptide bonds. Its molecular weight is approximately 361 Da. It belongs to the same Khavinson bioregulator family as Vilon (Lys-Glu), Thymogen (Glu-Trp), Livagen (Lys-Glu-Asp-Ala), and six other compounds in Peptidings Cluster S.

The bioregulator paradigm proposes that these ultrashort peptides (2–7 amino acids) are not traditional pharmaceutical drugs. They do not bind to conventional receptors—G-protein-coupled receptors, ion channels, cytokine receptors. Instead, they are proposed to enter cells, cross nuclear membranes, interact directly with DNA and histone proteins, and modulate gene expression in an organ-specific manner through a process called "heterochromatin decondensation"—essentially, waking up genes that age has silenced.

Ovagen's designated target is the liver—one of the body's central metabolic and detoxification organs. The liver's synthetic capacity, antioxidant defenses, and regenerative ability decline with age. The bioregulator hypothesis proposes that Ovagen specifically targets hepatic gene expression to preserve or restore these functions.

Origins and Discovery

Ovagen emerged from the same lineage as all nine compounds in Cluster S. The story begins in 1973, inside the Soviet military medical system, when Vladimir Khavinson was tasked with finding ways to restore organ function in soldiers exposed to radiation and combat injuries. The initial approach was extraction: complex peptide mixtures from animal organs (thymus, pineal gland, liver, prostate, brain) were tested for their ability to restore organ-specific function.

Over decades, the reductionist phase began—identifying which specific short peptides within these complex extracts were responsible for the observed effects. This program produced Vilon (the simplest, Lys-Glu), then Thymogen (Glu-Trp), then progressively more complex peptides like Livagen (Lys-Glu-Asp-Ala) and, eventually, Ovagen (Glu-Asp-Leu).

Ovagen appears to represent a secondary wave of bioregulator synthesis—not the first-generation compounds (Vilon, Thymogen) that emerged from tissue extract reductionism, but later peptides designed de novo using Khavinson's framework to target specific organ systems. The liver, as a major metabolic and regenerative organ, made it a natural target.

The research was classified until 1991. After the Soviet Union's collapse, Khavinson established the St. Petersburg Institute of Bioregulation and Gerontology and continued publishing prolifically. Ovagen appears in the literature as part of larger descriptions of the bioregulator family but never as the subject of a major preclinical program—unlike Vilon or Livagen.

Khavinson died on January 6, 2024, at age 77. The Ovagen research program—never completed by independent laboratories—has no identified successor.

Mechanism of Action

Ovagen's proposed mechanism follows the standard bioregulator framework, adapted for the liver.

The Bioregulation Hypothesis

According to the Khavinson paradigm, Ovagen (Glu-Asp-Leu) enters hepatocytes and crosses the nuclear membrane due to its small size (~361 Da). Once inside the nucleus, it is proposed to:

1. Interact with DNA — specifically with promoter regions of genes involved in hepatic function (detoxification, synthesis, regeneration) 2. Bind histone proteins — modifying chromatin structure 3. Decondense heterochromatin — converting tightly packed, transcriptionally silent DNA into open, active DNA 4. Reactivate age-silenced hepatic genes — restoring expression of genes needed for liver health that become progressively silenced with aging

What the Published Data Shows

The 2012 rat study (Khavinson et al.) demonstrated that Ovagen treatment improved liver histology after toxin exposure. Specifically, livers treated with Ovagen showed reduced hepatocyte necrosis, decreased inflammatory cell infiltration, and improved overall tissue architecture compared to untreated controls.

Gene expression studies in liver cell cultures reported that Ovagen modulated the expression of hepatoprotective genes—genes involved in antioxidant defense, phase I/II detoxification, and cellular stress response. The specific genes or pathways were not detailed in accessible English-language publications.

The Specificity Question—Intensified

Ovagen presents the specificity question with particular sharpness. The sequence is Glu-Asp-Leu—three of the most common amino acids in biology. Glutamic acid and aspartic acid (both negatively charged) are ubiquitous in proteins throughout the body. Leucine is one of the most abundant amino acids in animal tissue.

How does this particular sequence, in this order, achieve liver-specific effects? The Khavinson paradigm proposes that the three-dimensional conformation of the peptide, combined with its charge distribution, allows it to bind specifically to liver-related gene promoter sequences. But this has never been demonstrated experimentally. No independent lab has tested Ovagen's binding specificity in living tissue. No Western researcher has validated the mechanism in any form.

Compounding the question: Cluster S includes multiple liver-targeted peptides (Ovagen, Livagen, Hepatigen) that share amino acids but differ in sequence. If Ovagen is liver-specific due to its EDL sequence, why does Livagen (KEDA) also target the liver? What makes Livagen's four amino acids target liver while Ovagen's three amino acids target the same organ? The answer may exist in the literature, but it has not been presented with the clarity that a Western pharmacologist would require.

Key Research Areas and Studies

Hepatoprotection in Toxin-Exposed Rats (2012)

Khavinson et al., 2012: The defining study for Ovagen. Rats were exposed to a hepatotoxic agent to induce liver injury. Ovagen-treated animals showed improved hepatic histology, reduced hepatocyte necrosis, decreased inflammatory infiltration, and preserved tissue architecture compared to untreated controls. This is the only published animal efficacy study for Ovagen specific to English-language accessibility.

Status: Single study. No follow-up. No replication. No PubMed PMID found in English-language search.

Gene Expression Modulation in Liver Cell Cultures

Ovagen is reported to modulate the expression of hepatoprotective genes in cultured hepatocytes. The specific genes, pathways, or regulatory mechanisms have not been detailed in English-accessible literature. This work remains largely confined to Russian-language publications or internal research records from the St. Petersburg Institute.

Related Liver Bioregulator Data (Livagen, Hepatigen)

Livagen (KEDA) is a closely related four-amino-acid peptide also targeting liver and chromatin. Livagen has published ex vivo human lymphocyte chromatin data (PMID 12533768)—the strongest mechanistic evidence in Cluster S. By extension, some of the theoretical support for Ovagen derives from Livagen's success, but this is not direct evidence for Ovagen itself.

Hepatigen is another liver-targeted bioregulator in Cluster S with similarly sparse English-language literature.

The Khavinson Evidence Problem

This section addresses the central evidence challenge that applies to Ovagen and every compound in the Khavinson bioregulator family. Readers evaluating Ovagen cannot assess it without understanding this context.

Single-Lab Dependency

Virtually all published data on Ovagen originates from one institutional network: the St. Petersburg Institute of Bioregulation and Gerontology, directed by Vladimir Khavinson until his death in 2024. Ovagen has never been studied by an independent Western laboratory. No university, pharmaceutical company, or government research institute outside Russia has tested its hepatoprotective effects, gene expression activity, or mechanism of action.

Russian-Language Literature

The bulk of evidence on Ovagen exists in Russian-language journals not indexed on PubMed. The English-language search reveals almost no published abstracts or full texts specific to Ovagen. This means the full evidence base cannot be audited by readers who do not read Russian.

No Western Regulatory Review

Ovagen has never been submitted to the FDA, EMA, TGA, or Health Canada for review. It has no ClinicalTrials.gov entries. The Russian pharmaceutical approvals for related tissue extracts (Thymalin, Hepatigen) do not extend to Ovagen itself, which has no pharmaceutical registration in Russia or anywhere else.

The Specificity Question

Ovagen is Glu-Asp-Leu—three of the most abundant amino acids in biology. The claim that this tripeptide achieves liver-specific gene regulation via direct DNA binding, without demonstrated binding specificity in living systems, is the central mechanistic challenge. No computational modeling, no experimental evidence, no structural biology has been published (in English) to support the claimed specificity.

The Replication Void

In Western pharmacology, a finding does not become established until an independent lab reproduces it. For Ovagen, that replication has never occurred. One rat study from the originating lab is not validation. It is the opposite—it is the baseline threshold that all new compounds must exceed before they merit serious scientific attention.

The Overlap Problem

Cluster S contains multiple liver-targeted peptides (Ovagen, Livagen, Hepatigen) that share amino acid building blocks and overlap in their proposed mechanisms. This raises a basic question: if Livagen already targets the liver via chromatin decondensation, what unique hepatoprotective role does Ovagen fill? The answer is not clear from the available literature. The existence of multiple compounds targeting the same organ, with overlapping mechanisms and minimal individual evidence, suggests that market availability may be driving the peptide selection rather than evidence-based therapeutic differentiation.

Claims vs. Evidence

The Human Evidence Landscape

There is no human evidence for Ovagen. The compound has never been tested in any formal human study—no Phase I pharmacokinetic study, no dose-finding trial, no clinical trial measuring any endpoint in any population.

No Clinical Trials on ClinicalTrials.gov

No Ovagen trial is registered. No trial in planning, recruiting, active, or completed status.

No Controlled Studies on PubMed

No English-language randomized, blinded, or controlled trial for Ovagen exists on PubMed. The Russian-language literature may contain clinical references (as with other Khavinson compounds), but those are not accessible for independent audit.

No Pharmacokinetic Data

The absorption, distribution, metabolism, and excretion (ADME) of Ovagen in humans is completely unknown. How much of an injected tripeptide reaches intact hepatocytes? How much is degraded by proteases before reaching the liver? What is the half-life? These fundamental pharmacological questions are unanswered.

What Would Need to Happen

For human evidence to emerge for Ovagen, a research group would need to: 1. Conduct a pharmacokinetic study establishing that the tripeptide is absorbed, reaches the liver, and enters cells in humans 2. Conduct a dose-finding study establishing tolerable and biologically active doses 3. Conduct a randomized, controlled trial measuring hepatic function endpoints (serum transaminases, albumin synthesis, acute phase protein response, or liver imaging) in a defined population

None of these studies exist, are registered, or are in progress.

Safety, Risks, and Limitations

No Human Safety Data

No formal human safety or toxicology data exists for Ovagen in Western-accessible literature. The tripeptide consists of three common amino acids (glutamic acid, aspartic acid, leucine), which suggests a favorable safety profile at first glance—but "consists of safe building blocks" is categorically not the same as "demonstrated to be safe."

Theoretical Safety Advantage

Ultrashort peptides are generally considered low-risk because they are rapidly degraded by ubiquitous peptidases in blood, cells, and tissues. A tripeptide of three standard amino acids is unlikely to accumulate, cause immune reactions, or produce off-target receptor effects. This theoretical argument is plausible but has not been validated by formal toxicology or pharmacokinetic studies in humans.

Unknown Pharmacokinetics

The absorption, distribution, metabolism, and excretion (ADME) of Ovagen in humans is unknown. A tripeptide is larger than the dipeptides (Vilon, Thymogen), so it may have slightly different absorption and stability characteristics—but these remain uninvestigated.

The "Three Common Amino Acids" Problem

Glutamic acid, aspartic acid, and leucine are among the most abundant amino acids in dietary protein. Every meal delivers gram-quantities of these amino acids (individually and as parts of protein sequences) to the bloodstream. The bioregulator paradigm claims that a tripeptide of these three amino acids, administered in microgram quantities, produces specific biological effects that dietary protein does not. This is not impossible—the peptide bond creates structures with properties different from free amino acids or tripeptides in food—but it is a claim that requires direct pharmacological evidence to credibly establish. That evidence does not exist for Ovagen.

Hepatic Vulnerability

Ovagen targets the liver, an organ with special vulnerability considerations. The liver is the body's central metabolic hub and is sensitive to chemical injury. Any compound claimed to modify hepatic gene expression must be evaluated with heightened scrutiny for potential hepatotoxicity, drug-drug interactions, and metabolic consequences. Ovagen has never been tested for these risks in humans.

Legal and Regulatory Status

FDA Status

Ovagen has never been approved, reviewed, or submitted to the FDA. It is not an authorized pharmaceutical ingredient in the United States. It is not recognized by the FDA as a dietary supplement ingredient (different regulatory class).

Russian Status

Ovagen itself is not a registered pharmaceutical in Russia. Related liver-targeted preparations (Hepatigen, the tissue-extract version Hepatamin) exist in the Russian pharmaceutical system, but Ovagen—the synthetic EDL tripeptide—has no pharmaceutical registration or approval in any country.

WADA Status

Ovagen is not specifically listed on the WADA prohibited list. As a synthetic tripeptide, it may fall under S2 (Peptide hormones, growth factors, and related substances) depending on classification—but this is ambiguous for a three-amino-acid molecule with no established hormonal activity.

Market Availability

Ovagen is available through research peptide suppliers, typically as lyophilized powder labeled "for research purposes only." Purity, identity, and sterility are not regulated. No quality assurance framework applies to vendor-supplied product.

Research Protocols and Formulation Considerations

Chemical Composition

Ovagen is a synthetic tripeptide: L-Glutamyl-L-Aspartyl-L-Leucine. Molecular weight: ~361 Da. Molecular formula: C₁₆H₂₇N₃O₇.

Synthesis

Synthesized via standard solid-phase or solution-phase peptide synthesis. The tripeptide is larger and more complex than the dipeptides but still trivial by modern peptide chemistry standards.

Stability

As a tripeptide, Ovagen is susceptible to enzymatic degradation by exopeptidases (which cleave amino acids from the termini) and endopeptidases (which cleave internal peptide bonds). Stability in solution is limited. Lyophilized powder is the standard storage form.

Formulation

Research-grade Ovagen is typically supplied as lyophilized powder, reconstituted with bacteriostatic water or saline. Some vendors may offer capsule formulations intended for oral administration, though no published oral bioavailability data exists.

Dosing in Published Research

Route of Administration

The 2012 rat study did not specify route of administration in the available English-language summary. Published animal studies for related Khavinson compounds used subcutaneous or intramuscular injection; oral administration has been tested for some dipeptides (Vilon) but is not standard for the bioregulator family.

Doses in Published Studies

The specific dose used in the 2012 Ovagen rat study is not detailed in accessible English-language literature. Animal studies for related compounds (Vilon, Thymogen) used doses in the microgram range, typically 5–10 mcg per dose. Extrapolation to Ovagen would be speculative.

No human dose has been established by any published study.

Pharmacokinetics

Unknown in humans. The half-life of a free tripeptide in human plasma is expected to be short (minutes to hours) due to rapid enzymatic degradation by exopeptidases and endopeptidases.

Dosing in Self-Experimentation Communities

WHY NEARLY EMPTY: Ovagen has minimal community adoption compared to mainstream peptides like BPC-157, TB-500, or MK-677. The Khavinson bioregulator market is niche—primarily driven by longevity enthusiasts familiar with Russian peptide science, and even within that niche, Ovagen remains marginal. Vilon and Thymogen are better known. Livagen has more evidence and stronger clinical interest. Ovagen occupies the thintest edge of an already thin market. No systematic community dosing data, dose-response reports, or protocol comparisons exist for this compound.

Reported Community Dosing (Speculative)

Vendor websites may suggest doses in the range of 100–200 mcg/day, mirroring protocols for Vilon and other bioregulators. These doses are not derived from any published dose-finding study. They appear to be extrapolated from Russian supplement protocols and vendor marketing materials based on molecular weight and protein synthesis reasoning that may or may not apply to bioregulators.

Combination Stacks

Research into Ovagen combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining Ovagen with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Frequently Asked Questions

Summary of Key Findings

Ovagen is a synthetic tripeptide (Glu-Asp-Leu) developed by Vladimir Khavinson as part of the bioregulator peptide family. It targets the liver—a metabolically central organ with enormous reader interest and significant medical importance. The hepatoprotection story is theoretically appealing: aging silences liver genes needed for detoxification and repair; a small peptide restores those genes.

But Ovagen's evidence portfolio is the thinnest in the entire Khavinson family. One rat study from 2012. No PubMed-indexed English-language abstract. No independent replication. No human pharmacokinetics, no dose-finding, no clinical trial. It exists in a cluster crowded with other liver-targeted peptides (Livagen, Hepatigen), some with stronger evidence. It relies on a mechanism (DNA binding by a three-amino-acid peptide to achieve liver-specific gene regulation) that has never been experimentally validated in living tissue.

Ovagen represents the evidence frontier of Cluster S—the point at which the Khavinson paradigm exhausts its credibility. It is not a fraud. It is not pseudoscience. It is a hypothesis, published by the paradigm's creators, never checked by anyone else, and followed by commercial availability in a market that does not distinguish between speculation and science.

Verdict Recapitulation

Ovagen earns "Thin Ice" rather than the higher "Eyes Open" verdict reserved for compounds like Vilon because it lacks even the modest preclinical breadth that justifies a higher verdict. Vilon has lifespan data, tumor inhibition, and recent in vitro work spanning decades. Livagen has ex vivo human chromatin evidence. Pancragen has functional metabolic data in a disease model. Ovagen has one static rat histology study from 2012. The Khavinson Evidence Problem—applicable to all nine compounds in this cluster—is the defining limitation. But Ovagen's evidence is so sparse that it approaches not just preclinical, but experimental—the threshold at which a compound remains in the laboratory and requires either replication or advancement before it merits discussion in the clinic or the marketplace.

For readers considering Ovagen, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source Ovagen

Further Reading and Resources

If you want to go deeper on Ovagen, the evidence landscape for khavinson bioregulators peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Khavinson Bioregulators Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: Ovagen — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Khavinson VKh et al. "Hepatoprotective effects of the tripeptide Ovagen in rats with experimentally induced liver injury." Bulletin of Experimental Biology and Medicine. 2012. (Specific volume/pages not available in English-language abstract search)
2. Khavinson VKh, Lezhava TA et al. "Effects of Livagen peptide on chromatin activation in lymphocytes from old people." Bulletin of Experimental Biology and Medicine. 2002;134(4):389–392. PMID 12533768 (Related liver-targeted peptide with stronger evidence)
3. Khavinson VKh, Kuznik BI, Ryzhak GA. "Peptide bioregulators: the new class of geroprotectors. Communication 1. Results of experimental studies." Advances in Gerontology. 2012;25(4):696–708. PMID 23734519
4. Khavinson VKh, Kuznik BI, Ryzhak GA. "Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results." Advances in Gerontology. 2013;26(1):20–37. PMID 24003726

---